Cargando…

Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay

BACKGROUND: Acute bacterial skin and skin structure infections (ABSSSI) are a rapidly increasing cause of hospitalization. Prolonged length of stay (LOS) increases the cost burden to health systems due to administration of parenteral antimicrobials. Dalbavancin is a lipoglycopeptide providing a full...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Bruce, Hersey, Roby, Crosby, Joseph, Bland, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631790/ http://dx.doi.org/10.1093/ofid/ofx163.804

Ejemplares similares

1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection
por: Kim, Sonia S, et al.
Publicado: (2021)

1556. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in a self-pay population
por: Murray, E Yancey, et al.
Publicado: (2020)

Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients
por: Pizzuti, Adam G., et al.
Publicado: (2020)

Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial
por: McCarthy, Matthew W., et al.
Publicado: (2019)

456. Dalbavancin, a Long-Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)—the ENHANCE ABSSSI Trial
por: McCarthy, Matthew W, et al.
Publicado: (2019)

Use of Penicillin Skin Testing as an Antimicrobial Stewardship Initiative: Clinical and Economic Evaluation at a Community Health System
por: Jones, Bruce, et al.
Publicado: (2017)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

To Add or Not to Add: Would the Addition of Dalbavancin to Formulary Decrease Admissions for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)?
por: Freshwater, Dustin, et al.
Publicado: (2017)

1790. Clinical and Economic Outcome Evaluation with Penicillin Skin Testing as an Antimicrobial Stewardship Initiative in a Not-for-Profit Community Health System
por: Jones, Bruce M, et al.
Publicado: (2018)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

2370. Dalbavancin Use in Emergency Department and Observation Unit to Prevent Inpatient Admission for Acute Bacterial Skin and Skin Structure Infection (ABSSI)
por: Ford, Jonathan, et al.
Publicado: (2018)

Transition of Care with Dalbavancin: a Successful Cost-Saving Stewardship Program through Decreased Length of Stay
por: Terriff, Colleen
Publicado: (2017)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
por: Leuthner, Kimberly D, et al.
Publicado: (2016)

Impact of an Antimicrobial Stewardship and Emergency Department Initiated Dalbavancin Guideline for Patients with Acute Bacterial Skin and Soft-Tissue Infections
por: Burgess, Donna R, et al.
Publicado: (2017)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections
por: Poliseno, Mariacristina, et al.
Publicado: (2021)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
por: Juul, Janelle J, et al.
Publicado: (2016)

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections
por: Giorgobiani, Manana, et al.
Publicado: (2022)

1385. Pathway with single-dose long-acting intravenous antibiotic dalbavancin is a cost-saving alternative to usual inpatient care of acute bacterial skin and skin structure infections (ABSSSI)
por: Lovecchio, Frank, et al.
Publicado: (2022)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

2362. Emergency Department Resource Utilization After Implementation of a Dalbavancin Pathway for Skin and Soft-Tissue Infections
por: Heil, Emily, et al.
Publicado: (2018)

Impact of clinical pharmacist intervention on acute admission unit length of stay
por: Lind, Katrine B, et al.
Publicado: (2015)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
por: Dunne, Michael W., et al.
Publicado: (2016)

Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals
por: Bai, Francesca, et al.
Publicado: (2023)

1811. Impact of a one-time oritavancin infusion on hospital length of stay for uncomplicated skin and soft tissue infections
por: Bremmer, Derek N, et al.
Publicado: (2023)

Clinical and Economic Outcomes of Penicillin Skin Testing as an Antimicrobial Stewardship Initiative in a Community Health System
por: Jones, Bruce M, et al.
Publicado: (2019)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
por: Bennett, Jason W, et al.
Publicado: (2008)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials
por: Riccobene, Todd, et al.
Publicado: (2023)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

Examination of hospital length of stay in Canada among patients with acute bacterial skin and skin structure infection caused by methicillin-resistant Staphylococcus aureus
por: Potashman, Michele H, et al.
Publicado: (2016)

1660. Dalbavancin Utilization Registry Investigating Value and Effectiveness (DRIVE): Outcomes Report on Real-World Use
por: Jones, Bruce M, et al.
Publicado: (2022)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
por: Stroffolini, Giacomo, et al.
Publicado: (2022)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g570v0l04eelmblq4fcn6pidpt